All roads lead to targeted diffuse large B-cell lymphoma approaches

Article Oncology

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Wyndham H. Wilson et al.

Summary: In younger patients with non-GCB DLBCL, the addition of ibrutinib to R-CHOP chemotherapy improves survival rates, particularly in patients with MCD and N1 subtypes. This study provides mechanistic understanding of the benefit of ibrutinib in this patient population.

CANCER CELL (2021)

Add to Collection

Article Oncology

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

Nikita Kotlov et al.

Summary: In this study, a transcriptomic analysis of the microenvironment of DLBCL was conducted, revealing four major lymphoma microenvironment categories associated with distinct biological aberrations and clinical behavior. This research also identified genetic and epigenetic mechanisms used by cancer cells to evade microenvironmental constraints and suggested the use of DNA hypomethylating agents in selected DLBCL patients. Additionally, new therapeutic vulnerabilities in the extracellular matrix composition were uncovered, providing potential targets for decreasing DLBCL proliferation in preclinical models.

CANCER DISCOVERY (2021)

Add to Collection

Article Hematology

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu et al.

BLOOD (2020)

Add to Collection

Article Oncology

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

George W. Wright et al.

CANCER CELL (2020)

Add to Collection

Article Oncology

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

M. J. Maurer et al.

ANNALS OF ONCOLOGY (2018)

Add to Collection

Article Oncology

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

All roads lead to targeted diffuse large B-cell lymphoma approaches

Related references

Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Export Citation

Share Paper